- $801.08m
- $669.44m
- $0.21m
U.S. STOCKS ON THE MOVE-Moderna, Hims & Hers Health, Carrier
Chimerix surges on Jazz Pharma's $935 million buyout
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-AppLovin, crypto stocks, KKR
Brief: Jazz Pharmaceuticals Upon Termination Of Deal Chimerix Will Be Required To Pay Termination Fee Of $35 Million In Cash
Brief: Jazz Pharmaceuticals To Acquire Chimerix
Chimerix surges on Jazz Pharma's $935 million buyout
Jazz Pharmaceuticals to buy Chimerix for $935 million (updated)
Jazz Pharmaceuticals to buy Chimerix for $935 million
Chimerix Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone
Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug
Brief: Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27m-Mutant Diffuse Glioma Before Year-End
Brief: Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Chimerix Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Chimerix Reports Q3 2024 Financial Results And Provides Operational Update
Brief: Chimerix Q3 EPS USD -0.26
Chimerix Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Chimerix To Report Third Quarter 2024 Financial Results